Semergen. 2026 Jul 7;52(6):102799. doi: 10.1016/j.semerg.2026.102799. Online ahead of print.
ABSTRACT
Cardiovascular diseases continue to be the leading cause of morbidity and mortality worldwide. Reducing LDL cholesterol (LDL-c) is one of the fundamental pillars of cardiovascular prevention; however, a significant percentage of patients do not reach the recommended therapeutic targets with first-line treatment. PCSK9 inhibitors have demonstrated significant reductions in LDL-c and decreased cardiovascular events in high- and very high-risk patients. The 2025 update of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guidelines for the management of dyslipidemias reinforces the concept of the earlier and the lower, the better, as well as the need for early combination therapies.
PMID:42413166 | DOI:10.1016/j.semerg.2026.102799